Browse News
Filter News
Found 85 articles
-
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy
2/16/2024
Otsuka Pharmaceutical Development & Commercialization, Inc., ; Otsuka Pharmaceutical, Co. Ltd. ; and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy.
-
New England Journal of Medicine Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab in Treatment of Immunoglobulin A Nephropathy (IgAN)
11/2/2023
Otsuka Pharmaceutical Development & Commercialization, Inc. and Visterra Inc., today announced that the full results of a Phase 2 trial of sibeprenlimab (VIS649) for treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease) have been published in the New England Journal of Medicine.
-
A paper published by Tillman Gerngross, chief executive officer of Adimab LLC, alleged that an MIT professor's work was nearly identical to work published several years before his.
-
Home to many of the world's leading life science companies, the Genetown hotbed is a hub of activity. To help you in your job search, here are 10 Massachusetts biopharma companies hiring now.
-
KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman
10/17/2022
KalVista Pharmaceuticals, Inc. announced that the Board of Directors has appointed current member Brian J.G. Pereira, M.D., as Chairman, effective immediately.
-
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
8/11/2022
ProKidney Corp., a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease, announced the appointments of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors.
-
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III
7/12/2022
ProKidney LP, a leading late clinical-stage cellular therapeutics company focused on CKD, and Social Capital Suvretta Holdings Corp. III, a special purpose acquisition company, completed their previously announced business combination.
-
Vaxess Bolsters Commitment To Vaccine Patch Leadership With Purpose-Built Cambridge Lab And Fortified Management Team With The Addition Of A Veteran CFO And Head Of Device Development
3/1/2022
Vaxess Technologies, Inc., an innovative life sciences company developing a pipeline of shelf-stable and simple-to-apply vaccines on the MIMIX patch platform announced occupancy of a second new facility and significant additions to the leadership team.
-
Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer
2/3/2022
Tarsus Pharmaceuticals, Inc., whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer.
-
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III
1/18/2022
ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”), has entered into a definitive agreement to become a publicly traded company.
-
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore's Experimental Drug Development Centre's 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide
1/13/2022
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), and Singapore's Experimental Drug Development Centre ("EDDC") today announced a global licensing agreement under which Everest will obtain exclusive worldwide rights to develop, manufacture and commercialize EDDC's series of viral 3C-like ("3CL") protease inhibitors as potentially best-in-class COVID-19 oral antiviral treatments.
-
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
1/4/2022
Alnylam Pharmaceuticals, Inc. today announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President.
-
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
8/3/2021
Seres Therapeutics, Inc., a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, reported second quarter 2021 financial results and provided business updates.
-
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
5/20/2021
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that David Arkowitz will join as Executive Vice President, Chief Financial Officer (CFO) and Head of Business Development, effective June 1, 2021. Mr. Arkowitz will report directly to Eric Shaff, President and Chief Executive Officer of Seres.
-
RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
-
Atalanta Therapeutics Launches With $110 Million to Pioneer RNAi Therapeutics for Neurodegenerative Diseases
1/11/2021
Announces strategic collaborations with Biogen, Genentech to develop RNAi therapeutics for neurodegenerative diseases
-
Voltron Therapeutics Publishes Letter to Shareholders
5/19/2020
Voltron Therapeutics, Inc. announces today a letter to the shareholders. Dear Voltron Therapeutics shareholders, We hope this letter finds you well during this remarkable time. We would also like to thank for your support of Voltron. The current COVID-19 pandemic is exactly the kind of situation that our VaxCelerate platform was cr
-
Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of DirectorsCompany appoints experienced industry leaders Brian Pereira as Executive Chairman and Shawn Tomasello as Independent Board Member
4/21/2020
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced appointments of Brian Pereira, M.D. and Shawn Tomasello, M.B.A. as Executive Chairman and Independent Board Member, respectively. “On behalf of the Board, I am pleased to welcome Brian and Shawn, and look forward to collaborating with them as we guide Abeona to success,” said Steven H. Rouhandeh, former Executive Chairman and
-
Bernadette Connaughton Appointed to Syneos Health Board of Directors
11/12/2019
With Connaughton’s appointment, the Company’s Board has been expanded from 10 to 11 directors, 10 of whom are independent.
-
SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer
6/25/2019
SmartPharm Therapeutics announced that José Trevejo, MD, PhD, has been appointed Chief Executive Officer.